 |
 |
 |
|
COMPARISON OF VIRAL REPLICATION AT <40 C/ML FOR 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE
(DTG/3TC FDC) VERSUS 3-DRUG REGIMEN (3DR) BASED ON TENOFOVIR ALAFENAMIDE (TAF) (TBR) IN THE TANGO STUDY
|
|
|
IAC 2020 Virtual July 6-10
Reported by Jules Levin
Ruolan Wang,1 Jonathan Wright,2 Mounir Ait-Khaled,3 Thomas Lutz,4 Olayemi Osiyemi,5 Miguel Gorgolas,6 Rifaz Razeek,2 Manrajdeep Virk,2
Maria Claudia Nascimento,3 Allan R. Tenorio,1 Mark Underwood1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Brentford, UK; 4Infektio Research, Frankfurt, Germany; 5Triple O Research Institute PA,
West Palm Beach, FL, USA; 6Jiménez Díaz Foundation University Hospital, Madrid, Spain




|
|
|
 |
 |
|
|